365bet娱乐

In the past period of time, some reported therapeutic drugs still need more clinical practice to prove their effectiveness. Currently, at least seven small-molecule drugs targeting viral RNA polymerase or protease have been developed at different clinical research stages.

The earliest reported drug with a certain effect on new coronaviruses infection was reported by Wang Guangfa, the Director of Respiratory and Critical Illness, Peking University First Hospital, and member of the expert group of the National Health Commission. It is a drug called "Lopinavir and Ritonavir Tablets" (Kelizhi). It is a compound preparation, the two main ingredients, lopinavir and ritonavir, are protease inhibitors. They can be combined with the catalytic site of HIV protease and interfere with the assembly process of the virus. Therefore, it is used as an antiviral drug. This drug is clinically suitable for the combination with other antiretroviral drugs to treat HIV infection. Lu Hongzhou, a well-known expert in the field of infection and secretary of the Party Committee of the Shanghai Public Health Clinical Center, told the media recently that the new coronaviruses and HIV are RNA viruses that share some common features in treatment. It is indeed found in the clinic that the application of the anti-AIDS drug Kelizhi was very effective to treat new pneumonia patients. In the process of virus replication and assembly, the new coronaviruses may use some similar protein functions as HIV. "If HIV-specific protease inhibitors such as lopinavir and ritonavir can also bind to coronaviruses protease to inhibit their normal function, they can exert anti-coronaviruses effects," said Lu Hongzhou.

Recently, after the first confirmed case in the United States was treated with Remdesivir as a specific medicine, the disease showed rapid remission. Remdesivir was originally a drug used to treat Ebola virus. In its previous studies, it has been shown to have inhibitory effects on a variety of viruses, such as coronaviruses, hepatitis C virus, HIV virus, and Ebola virus. In its clinical study of Ebola virus, the results were not ideal, but its safety was acceptable. Based on current clinical results, Gilead Sciences said it offered experimental Ebola therapies for a small percentage of patients infected with coronaviruses. It is reported that Gilead's drug will undergo phase III clinical trials of coronaviruses in China. It is hoped that it will be applied to Chinese patients as soon as possible to provide strong support for fighting the new coronaviruses.

In addition to the two drugs reported above, the vast number of researchers in China are also fighting day and night to screen existing drugs in various ways, including the protease inhibitors of 12 anti-HIV drugs like Indinavir, Saquinavir, Lopinavir, Carfilzomib, Ritonavir. 2 anti-respiratory syncytial virus drugs, 1 anti-human macrophage drug, 1 anti-schizophrenia drugs, 1 immunosuppressant and 2 other drugs.

From the current results and the above research content, it can be found that the current research ideas are mainly focused on seeking the drug that can also inhibit new coronaviruses from clinically and marketed antiviral drugs. Based on this thinking, we think that  MK-8591 (EFDA) CAS NO:865363-93-5 should also be worth looking forward to its effect against the new coronaviruses disease.

MK-8591, also known as EFDA CAS NO:865363-93-5, was first discovered by Japanese scientists in 2001 in search of compounds that improved the taste of soy sauce. After confirming its structure, it was found to be close to some anti-HIV drugs. After further testing, it was found that MK-8591 has very high activity against HIV.

At present, the clinical research of MK-8591 CAS NO:865363-93-5 for the treatment of HIV is in clinical stage 2B. The results of clinical trials show that MK-8591 is expected to be the first oral HIV drug that can be taken weekly, either for treatment or prevention.

If the ability of MK-8591 CAS NO:865363-93-5 to prevent transmission can be equally effective in the treatment of new coronaviruses, then our work against new coronaviruses will be greatly reduced. Therefore,it is worthwhile to expect its effectiveness and safety against other viruses, including new coronaviruses.